Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign
June 22 2021 - 08:00AM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
and monitoring company with the mission to improve patient outcomes
by providing clear insights that inform critical decisions in the
diagnosis, treatment, and monitoring of cancer, announced today
that it is proud to present the #ShesMySurgeon campaign in honor of
outstanding women thoracic surgeons. #ShesMySurgeon was designed to
highlight women in the thoracic surgery field and their
accomplishments as an ongoing social media campaign, showcasing the
progress these women have made in a competitive field and ensuring
more work is done to achieve equal representation for women in
thoracic surgery.
“While the number of women residents and fellows
in thoracic surgery has increased in recent years, the US still
ranks 13th in percent of doctors who are women. We know this isn’t
for lack of talented and brilliant minds, and we think it’s
important to uncover and address potential barriers to entry into
the field,” said Sara Riordan, Head of Medical Education for
Oncocyte and President of the National Society of Genetic
Counselors. “We are honored to highlight these outstanding surgeons
and hope to make even a small difference in encouraging more and
more women to join this crucial specialty in cancer care.”
Women remain underrepresented across several
surgical specialties, with thoracic surgery a particularly obvious
gap. In the US, thoracic surgery has one of the lowest percentages
of women compared to other surgical and oncology specialties. The
American Board of Thoracic Surgery (ABTS) saw its first three women
members certified in 1961, and as of 2020, 353 women have become
ABTS diplomats – still only accounting for 3% of all thoracic
surgeons certified by the ABTS.
“As one of relatively few women in my field, the
acknowledgment of our expertise and achievements makes a
difference – we must take every chance we
have to build the community of female surgeons so we can work
together to advance cancer treatment,”
said Emily Cassidy, thoracic surgeon at Our Lady of
the Lake Mary Bird Perkins Cancer Center. “What we care about
the most is what all surgeons care about: saving lives in the
operating room and helping patients lead better lives. The more
female surgeons are encouraged to join the field, knowing they
can break barriers as others have done before them, the better off
we will be as a surgical oncology community.”
The collection of stories and illustrations can
be found on an ongoing basis on Oncocyte’s LinkedIn, Facebook,
and Twitter feeds. Oncocyte invites all who are, who know, or whose
lives have been impacted by a woman thoracic surgeon to interact
and follow along on social media at the hashtag #ShesMySurgeon,
with the hope that women surgeons will be able to connect with and
continue learning from each other through this campaign as
well.
Oncocyte is committed to fostering equal
representation for women and women of color throughout the cancer
care community, and aims to empower surgeons, physicians, and their
patients by providing confidence at every decision they will make
in their journey.
About OncocyteOncocyte is a precision
diagnostics and monitoring company with the mission to improve
patient outcomes by providing clear insights that inform critical
decisions in the diagnosis, treatment, and monitoring of cancer.
The Company, through its proprietary tests and pharmaceutical
services business, aims to help save lives by accelerating the
diagnosis of cancer and advancing cancer care. The Company’s tests
provide clarity and confidence at every stage. DetermaRx™
identifies early-stage lung cancer patients who are at high risk
for cancer recurrence and predicts benefit from adjuvant
chemotherapy. DetermaIO™, a gene expression test currently used as
a research tool in drug development, assesses the tumor
microenvironment to predict response to immunotherapies. The
Company’s robust pipeline of future tests also includes DetermaTx™,
which will assess mutational status of a tumor, blood-based
monitoring test DetermaCNI, and long-term recurrence monitoring
test DetermaMx™. In addition, Oncocyte’s pharmaceutical services
provide companies that are developing new cancer treatments a full
suite of molecular testing services to support the drug development
process.
DetermaRx, DetermaIO, DetermaTx, DetermaCNI and DetermaMx are
trademarks of Oncocyte Corporation.
Media Contacts
Terri ClevengerWestwicke/ICR Healthcare PRTel:
203.856.4326Terri.Clevenger@icrinc.com
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Mar 2023 to Mar 2024